Esta buscando: 1,4-Dioxaspiro[4.5]decan-8-ol

34 356 results were found

Refinar resultados Ordenado por

Sort Results

Vista lista Vista Extendida (Nueva)

Comparar(0) Clear

Valore los resultados de su búsqueda

6,10-Dibenzyl-N,N'-dimethyl-N,N,N',N'-tetrakis(4-methylbenzyl)-1,4-dioxaspiro[4.5]decane-(2R,3R)-diylbis(methylammonium)tetrafluoroborate [=(R,R)-TaDiAS-2nd] ≥97.0% (by total nitrogen basis)

Proveedor: TCI

Descripción: 6,10-Dibenzyl-N,N'-dimethyl-N,N,N',N'-tetrakis(4-methylbenzyl)-1,4-dioxaspiro[4.5]decane-(2R,3R)-diylbis(methylammonium)tetrafluoroborate [=(R,R)-TaDiAS-2nd] ≥97.0% (by total nitrogen basis)

1,4-Dioxa-8-azaspiro[4.5]decane ≥98.0% (by GC, titration analysis)

Proveedor: TCI

Descripción: 1,4-Dioxa-8-azaspiro[4.5]decane ≥98.0% (by GC, titration analysis)

1-Amino-4-oxocyclohexanecarboxylic acid ethylene ketal 98%

Numero del catalogo: (L19795.03)

Proveedor: Thermo Fisher Scientific

Descripción: 1-Amino-4-oxocyclohexanecarboxylic acid ethylene ketal 98%

UOM: 1 * 1 g

FDS Certificados Promoción

N/A Each

Bicyclohexane-4,4'-dione monoethylene ketal ≥98.0% (por GC)

Proveedor: TCI

Descripción: Bicyclohexane-4,4'-dione monoethylene ketal ≥98.0% (por GC)

2,2-Pentamethylene-1,3-dioxolane 95%

Proveedor: Apollo Scientific

Descripción: 2,2-Pentamethylene-1,3-dioxolane 95%

2,2-Pentamethylene-1,3-dioxolan-4-one ≥98.0% (por GC)

Proveedor: TCI

Descripción: 2,2-Pentamethylene-1,3-dioxolan-4-one ≥98.0% (por GC)

WYE-125132 ≥99% (by HPLC)

Proveedor: ENZO LIFE SCIENCES

Descripción: Highly potent, ATP-competitive, and specific mTOR kinase inhibitor. Antiproliferative.

New Product

WYE-125132 ≥98%, crystalline solid

Proveedor: Cayman Chemical

Descripción: WYE-125132 is an ATP-competitive inhibitor of mTOR (IC50 = 0,19 nM) that inhibits signaling through both mTORC1 and mTORC2. It is selective for mTOR over phosphatidylinositol 3-kinase isoforms. WYE-125132 is effective against mTORC1 and mTORC2 in diverse cancer models, both in vitro and in vivo. Oral administration of WYE-125132 alone blocks mTOR signaling and prevents tumor growth in breast, lung, renal, and glioma cancer xenografts in mice, while combination therapy with the VEGF-inhibitor bevacizumab causes complete regression of A498 renal carcinoma tumors. In addition to its applications in cancer, WYE-125132 has been used to delineate novel aspects of mTOR signaling.